{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:19Z","timestamp":1780750759745,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":26,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_7","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:02:00Z","timestamp":1753707720000},"page":"119-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative Evaluation of Exon Skipping in Immortalized Muscle Cells in Vitro"],"prefix":"10.1007","author":[{"given":"Kenji Rowel Q.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/nat.2013.0461","volume":"24","author":"K Siva","year":"2014","unstructured":"Siva K, Covello G, Denti MA (2014) Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther 24:69\u201386","journal-title":"Nucleic Acid Ther"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJA Lee","year":"2013","unstructured":"Lee JJA, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3:144\u2013176","journal-title":"J Pers Med"},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1261\/rna.653607","volume":"13","author":"A Aartsma-Rus","year":"2007","unstructured":"Aartsma-Rus A, van Ommen G-JB (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609\u20131624","journal-title":"RNA"},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AEH Emery","year":"1991","unstructured":"Emery AEH (1991) Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1:19\u201329","journal-title":"Neuromuscul Disord"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304\u2013313","journal-title":"Ann Neurol"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77\u201393","journal-title":"Lancet Neurol"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/adc.2007.118141","volume":"93","author":"A Manzur","year":"2008","unstructured":"Manzur A, Kinali M, Muntoni F (2008) Update on the management of Duchenne muscular dystrophy. Arch Dis Child 93:986\u2013990","journal-title":"Arch Dis Child"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH et al (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90:3710\u20133714","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395","journal-title":"Genomics"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18:1995\u20132005","journal-title":"Mol Ther"},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4:199\u2013207","journal-title":"J Neuromuscul Dis"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu Q-L, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667\u2013676","journal-title":"Ann Neurol"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198\u2013203","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR14","unstructured":"U.S. Food and Drug Administration (2016) FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm. Accessed 30 Aug 2017"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545","journal-title":"Drug Des Devel Ther"},{"key":"7_CR16","unstructured":"Sarepta Therapeutics (2017) Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053). https:\/\/globenewswire.com\/news-release\/2017\/09\/06\/1108211\/0\/en\/Sarepta-Therapeutics-Announces-Positive-Results-in-Its-Study-Evaluating-Gene-Expression-Dystrophin-Production-and-Dystrophin-Localization-in-Patients-with-Duchenne-Muscular-Dystrop.html. Accessed 8 Sep 2017"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jpm7040013","volume":"7","author":"Q Nguyen","year":"2017","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7:13","journal-title":"J Pers Med"},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25:2561\u20132572","journal-title":"Mol Ther"},{"key":"7_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L et al (2015) In Silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10:e0120058","journal-title":"PLoS One"},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","volume-title":"Duchenne muscular dystrophy: methods and protocols","author":"T Shimo","year":"2018","unstructured":"Shimo T, Maruyama R, Yokota T (2018) Designing effective antisense oligonucleotides for exon skipping. In: Bernardini C (ed) Duchenne muscular dystrophy: methods and protocols. Humana Press, New York, pp 143\u2013155"},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A et al (2011) Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 1:34","journal-title":"Skelet Muscle"},{"key":"7_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF01233096","volume":"16","author":"C Webster","year":"1990","unstructured":"Webster C, Blau HM (1990) Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet 16:557\u2013565","journal-title":"Somat Cell Mol Genet"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42:8174\u20138187","journal-title":"Nucleic Acids Res"},{"key":"7_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012239","volume":"5","author":"T Saito","year":"2010","unstructured":"Saito T, Nakamura A, Aoki Y et al (2010) Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 5:e12239","journal-title":"PLoS One"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1474-9726.2007.00306.x","volume":"6","author":"C-H Zhu","year":"2007","unstructured":"Zhu C-H, Mouly V, Cooper RN et al (2007) Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 6:515\u2013523","journal-title":"Aging Cell"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of Morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213","journal-title":"Methods Mol Biol"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:05:45Z","timestamp":1780747545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":26,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}